Boryung Group 
Welcome,         Profile    Billing    Logout  
 22 Products   94 Diseases   22 Products   46 Trials   2720 News 


«12...15161718192021222324252627»
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Zepsyre (lurbinectedin) / PharmaMar, Jazz
    Journal:  The antitumor drugs trabectedin and lurbinectedin induce transcription-dependent replication stress and genome instability. (Pubmed Central) -  Jan 27, 2020   
    Given the increasing evidence that R-loops occur all over the genome, the ability of lurbinectedin and trabectedin to act on them may contribute to enhance their efficacy, opening the possibility that R-loops might be a feature shared by specific cancers. Implications: The data presented in this study provide the new concept that R-loops are important cellular factors that contribute to trabectedin and lurbinectedin anticancer activity.
  • ||||||||||  fimasartan (BR-A-657) / Boryung Group
    Clinical, Journal:  Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study. (Pubmed Central) -  Dec 23, 2019   
    Implications: The data presented in this study provide the new concept that R-loops are important cellular factors that contribute to trabectedin and lurbinectedin anticancer activity. Fimasartan resulted in better pulse pressure reduction with similar BP reduction efficacy and safety in hypertensive elderly patients compared with nonelderly patients.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PM1183-A-014-15: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (clinicaltrials.gov) -  Dec 23, 2019   
    P1/2,  N=150, Recruiting, 
    In a word, this study may provide more information for understanding the effect of inhibition of the aplidin on the LMW-PTP. Phase classification: P1 --> P1/2 | N=100 --> 150 | Trial completion date: May 2020 --> Nov 2021 | Trial primary completion date: May 2019 --> Nov 2020
  • ||||||||||  Kanarb (fimasartan) - Boryung Group, R / Pharm
    Trial completion, Trial completion date:  FABULOUS: Fimasartan Blood Pressure Lowering After Acute Stroke (clinicaltrials.gov) -  Nov 4, 2019   
    P=N/A,  N=1035, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019
  • ||||||||||  Clinical, Review, Journal:  Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. (Pubmed Central) -  Nov 2, 2019   
    Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer.
  • ||||||||||  Zepsyre (lurbinectedin) / PharmaMar
    Journal, Checkpoint inhibition:  Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. (Pubmed Central) -  Oct 26, 2019   
    Anticancer effects resulting from lurbinectedin treatment were boosted in combination with PD-1 and CTLA-4 double immune checkpoint blockade (ICB), and lurbinectedin combined with double ICB exhibited strong antineoplastic effects. Cured animals exhibited long term immune memory effects that rendered them resistant to rechallenge with syngeneic tumors underlining the potency of combination therapy with lurbinectedin.
  • ||||||||||  Zepsyre (lurbinectedin) / PharmaMar
    Lurbinectedin down-regulates ASCL1 transcription factor in Small Cell Lung Cancer (SCLC) (Board 161: Level 2 - Hall D) -  Oct 25, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_684;    
    We tested whether lurbinectedin shared a similar effect on transcriptomic profile as other known drug by dividing up and down regulated genes and testing their correlation to the drug-related gene profiles provided by the tool Enrichr, we found that lurbinectedin has a high correlation to the topoisomerase I inhibitor class. This finding deserves further experimental verifications also in view of potential clinical interest in the combination of lurbinectedin and topoisomerase I inhibitors.
  • ||||||||||  Aplidin (plitidepsin) / PharmaMar, Roche
    Review, Journal:  Plitidepsin for multiple myeloma. (Pubmed Central) -  Oct 22, 2019   
    This finding deserves further experimental verifications also in view of potential clinical interest in the combination of lurbinectedin and topoisomerase I inhibitors. No abstract available
  • ||||||||||  paclitaxel / Generic Mfg.
    Subungual metastasis of an endometrial carcinoma () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1231;    
    A weekly Carboplatinum and Paclitaxel chemotherapy with concomitant Denosumab was initiated...As confirmed by the literature, the occurrence of subungual metastasis is precursor to the rapid fatal progression of the disease. Beside the unexpected topography of the metastasis, the absence of an underlying bone involvement and the mild clinical manifestations were singular features of this progression pattern.
  • ||||||||||  BR101801 / Boryung Group
    Trial initiation date, Metastases:  BR-101801-CT-101: BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) (clinicaltrials.gov) -  Oct 15, 2019   
    P1,  N=90, Not yet recruiting, 
    Beside the unexpected topography of the metastasis, the absence of an underlying bone involvement and the mild clinical manifestations were singular features of this progression pattern. Initiation date: Nov 2019 --> Feb 2020
  • ||||||||||  fimasartan (BR-A-657) / Boryung Group
    Review, Journal:  Fimasartan: A new armament to fight hypertension. (Pubmed Central) -  Aug 30, 2019   
    Further, it is renoprotective and has proven beneficial in diabetes also. This article briefly discusses the pharmacology and clinical evidence with fimasartan with a short summary of previous angiotensin receptor blockers.
  • ||||||||||  Zepsyre (lurbinectedin) / PharmaMar
    Journal, BRCA Biomarker:  Lurbinectedin for BRCA-mutated advanced breast cancer. (Pubmed Central) -  Jun 15, 2019   
    Similar, main pharmacokinetic parameters were calculated with the concentrations obtained either thru this method or by using a chemically synthetized authentic standard. No abstract available